Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.

Lukesh JC 3rd, Carney DW, Dong H, Cross RM, Shukla V, Duncan KK, Yang S, Brody DM, Brütsch MM, Radakovic A, Boger DL.

J Med Chem. 2017 Sep 14;60(17):7591-7604. doi: 10.1021/acs.jmedchem.7b00958. Epub 2017 Aug 31.

2.

Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.

Allemann O, Cross RM, Brütsch MM, Radakovic A, Boger DL.

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3055-3059. doi: 10.1016/j.bmcl.2017.05.058. Epub 2017 May 18.

3.

Hanbury Brown and Twiss interferometry with twisted light.

Magaña-Loaiza OS, Mirhosseini M, Cross RM, Rafsanjani SM, Boyd RW.

Sci Adv. 2016 Apr 8;2(4):e1501143. doi: 10.1126/sciadv.1501143. eCollection 2016 Apr.

4.

Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.

Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, Sáenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R.

J Med Chem. 2014 Nov 13;57(21):8860-79. doi: 10.1021/jm500942v. Epub 2014 Oct 22.

5.

Regularity and predictability of human mobility in personal space.

Austin D, Cross RM, Hayes T, Kaye J.

PLoS One. 2014 Feb 27;9(2):e90256. doi: 10.1371/journal.pone.0090256. eCollection 2014.

6.

4-(1H)-Quinolones and 1,2,3,4-Tetrahydroacridin-9(10H)-ones prevent the transmission of Plasmodium falciparum to Anopheles freeborni.

Sáenz FE, Lacrue AN, Cross RM, Maignan JR, Udenze KO, Manetsch R, Kyle DE.

Antimicrob Agents Chemother. 2013 Dec;57(12):6187-95. doi: 10.1128/AAC.00492-13. Epub 2013 Sep 30.

7.

Quinolone-3-diarylethers: a new class of antimalarial drug.

Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CHM, Price RN, Avery VM, Angulo-Barturen I, Jiménez-Díaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK.

Sci Transl Med. 2013 Mar 20;5(177):177ra37. doi: 10.1126/scitranslmed.3005029.

8.

4(1H)-Quinolones with liver stage activity against Plasmodium berghei.

Lacrue AN, Sáenz FE, Cross RM, Udenze KO, Monastyrskyi A, Stein S, Mutka TS, Manetsch R, Kyle DE.

Antimicrob Agents Chemother. 2013 Jan;57(1):417-24. doi: 10.1128/AAC.00793-12. Epub 2012 Nov 5.

9.

Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.

Cross RM, Namelikonda NK, Mutka TS, Luong L, Kyle DE, Manetsch R.

J Med Chem. 2011 Dec 22;54(24):8321-7. doi: 10.1021/jm200718m. Epub 2011 Nov 23.

PMID:
22111907
10.

Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.

Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.

J Med Chem. 2011 Jul 14;54(13):4399-426. doi: 10.1021/jm200015a. Epub 2011 Jun 16.

PMID:
21630666
11.

Divergent route to access structurally diverse 4-quinolones via mono or sequential cross-couplings.

Cross RM, Manetsch R.

J Org Chem. 2010 Dec 17;75(24):8654-7. doi: 10.1021/jo1014504. Epub 2010 Nov 17.

PMID:
21082793
12.

Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.

Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R.

J Med Chem. 2010 Oct 14;53(19):7076-94. doi: 10.1021/jm1007903.

PMID:
20828199
13.

Exploring attitudes: the case for Q methodology.

Cross RM.

Health Educ Res. 2005 Apr;20(2):206-13. Epub 2004 Sep 22.

PMID:
15385430
14.

Primary malignant lymphoma of the rectum (22 cases).

Perry PM, Cross RM, Morson BC.

Proc R Soc Med. 1972 Jan;65(1):72. No abstract available.

15.
16.

Hodgkin's disease: a possible experimental model in rats.

Gillman T, Kinns M, Cross RM.

Lancet. 1969 Dec 27;2(7635):1421-2. No abstract available.

PMID:
4188296
17.
18.
19.

Hernia uteri inguinalis in a male.

Binns JH, Cross RM.

Br J Surg. 1967 Jun;54(6):571-5. No abstract available.

PMID:
6067385
20.

Fibrosarcoma of the larynx.

Flanagan P, Cross RM, Libcke JH.

J Laryngol Otol. 1965 Dec;79(12):1049-56. No abstract available.

PMID:
5858165
21.

Necrotizing arteritis with giant cells associated with haemolytic anaemia.

Flanagan P, McCracken AW, Jones FR, Cross RM.

J Clin Pathol. 1965 Sep;18(5):588-92.

22.

SQUAMOUS CARCINOMA OF THE LUNG WITH OSTEOCARTILAGINOUS STROMA.

FLANAGAN P, MCCRACKEN AW, CROSS RM.

J Clin Pathol. 1965 Jul;18:403-7.

23.

Is nocardia asteroides an opportunist?

CROSS RM, BINFORD CH.

Lab Invest. 1962 Nov;11:1103-9. No abstract available.

PMID:
14024007
24.
25.

Vaccination technique and the control of smallpox epidemics.

CROSS RM.

Lancet. 1959 May 23;1(7082):1092-3. No abstract available.

PMID:
13655688
26.

Nasal glioma.

MORLEY GH, CROSS RM.

J Pathol Bacteriol. 1958 Oct;76(2):590-2. No abstract available.

PMID:
13588494
27.

Studies with dried and glycerinated smallpox vaccines of full and diminished potencies.

CROSS RM, KAPLAN C, McCLEAN D.

Bull World Health Organ. 1958;19(1):123-8.

28.

The heat resistance of dried smallpox vaccine.

CROSS RM, KAPLAN C, MCCLEAN D.

Lancet. 1957 Mar 2;272(6966):446-8. No abstract available.

PMID:
13407036
29.

Laboratory and vaccination studies with dried smallpox vaccines.

COCKBURN WC, CROSS RM, DOWNIE AW, DUMBELL KR, KAPLAN C, MCCLEAN D, PAYNE AM.

Bull World Health Organ. 1957;16(1):63-77.

Supplemental Content

Loading ...
Support Center